- Home
- SNGX vs SNSE Comparison
SNGX vs SNSE Comparison
Compare SNGX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- SNSE
- Stock Information
- Founded
- SNGX 1987
- SNSE 2005
- Country
- SNGX United States
- SNSE United States
- Employees
- SNGX N/A
- SNSE N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- SNSE Health Care
- Exchange
- SNGX Nasdaq
- SNSE Nasdaq
- Market Cap
- SNGX 13.8M
- SNSE 14.5M
- IPO Year
- SNGX 1987
- SNSE 2021
- Fundamental
- Price
- SNGX $1.34
- SNSE $8.68
- Analyst Decision
- SNGX Strong Buy
- SNSE Strong Buy
- Analyst Count
- SNGX 1
- SNSE 5
- Target Price
- SNGX $6.00
- SNSE $72.50
- AVG Volume (30 Days)
- SNGX 697.0K
- SNSE 79.0K
- Earning Date
- SNGX 11-10-2025
- SNSE 11-07-2025
- Dividend Yield
- SNGX N/A
- SNSE N/A
- EPS Growth
- SNGX N/A
- SNSE N/A
- EPS
- SNGX N/A
- SNSE N/A
- Revenue
- SNGX N/A
- SNSE N/A
- Revenue This Year
- SNGX N/A
- SNSE N/A
- Revenue Next Year
- SNGX N/A
- SNSE N/A
- P/E Ratio
- SNGX N/A
- SNSE N/A
- Revenue Growth
- SNGX N/A
- SNSE N/A
- 52 Week Low
- SNGX $1.09
- SNSE $5.00
- 52 Week High
- SNGX $6.23
- SNSE $18.35
- Technical
- Relative Strength Index (RSI)
- SNGX 34.06
- SNSE 42.27
- Support Level
- SNGX $1.54
- SNSE $8.33
- Resistance Level
- SNGX $1.61
- SNSE $12.40
- Average True Range (ATR)
- SNGX 0.10
- SNSE 1.94
- MACD
- SNGX 0.01
- SNSE -0.44
- Stochastic Oscillator
- SNGX 8.70
- SNSE 3.48
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).